Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2024 17:30 ET | Source: PMI

CBD Nutraceuticals Market is estimated to Reach USD 17.9 Billion by 2034, with a 16.40% CAGR and Meeting Growing Wellness Demands - By PMI

Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the CBD Nutraceuticals Market size was valued at about USD 4.5 Billion in 2024 and expected to grow at CAGR of...
August 12, 2021 16:05 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
August 05, 2021 08:00 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. to Announce Second Quarter 2021 Results on August 12, 2021

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
March 10, 2021 07:00 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. to Announce Fiscal Year and Fourth Quarter 2020 Results on March 18, 2021

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
December 08, 2020 07:00 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
August 06, 2020 16:05 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. Reports Second Quarter 2020 Financial Results

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
July 29, 2020 08:00 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. Announces Expansion with the Launch of CV™ Acute and New Immunity Product Line

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today...
May 20, 2020 16:30 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020

SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today...
May 20, 2020 08:00 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. Receives Formal Notice of Patent Issuance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction

SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
April 30, 2020 16:05 ET | Source: CV Sciences, Inc.

CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2020

SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...

Next Page keyboard_arrow_right